LFVNConsumer Defensive · Packaged FoodsThe 2 Wall Street analysts covering LifeVantage Corp. hold a median 12-month price target of $7.5 — +27.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 23 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores LifeVantage Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (18): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LFVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +27.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Aug 2026 | Lake Street | Maintains | Hold | $5.00 → $6.00 |
| 7 May 2026 | Lake Street | Downgrade | Hold | $5.00 |
| 7 May 2026 | Lake Street | Downgrade | Hold | — |
| 18 Feb 2026 | Freedom Broker | Maintains | Buy | — |
| 14 Nov 2025 | Freedom Broker | Maintains | Buy | — |
| 14 Jan 2025 | Craig-Hallum | Initiates | Buy | — |
| 19 Dec 2024 | Lake Street | Initiates | Buy | — |
| 12 Feb 2014 | Imperial Capital | Initiates | In-Line | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LFVN appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 23 Oct 2026, LifeVantage Corp. returned −31.2% against +14.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 47% of US stocks
Cheaper than 85% of US stocks
Cheaper than 40% of US stocks
Cheaper than 47% of US stocks
Higher than 10% of US stocks
Higher than 15% of US stocks
Higher than 89% of US stocks
Higher than 52% of US stocks
Higher than 54% of US stocks
Higher than 74% of US stocks
Higher than 82% of US stocks
Higher than 88% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
LifeVantage Corp. has a market value of $73.9M and an enterprise value of $69.9M.
Revenue in the twelve months to 30 June 2026: $182.6M. The latest quarter shrank 23.1% year on year.
Net income over the same four quarters: $5.1M, a 2.8% net margin.
Diluted earnings per share, trailing twelve months: $0.40.
Free cash flow in the twelve months to 30 June 2026: $6.7M.
LifeVantage Corp. spent $5.7M on share buybacks and $2.3M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 14.3×; forward P/E: 14.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 3.41%, paying out 46% of earnings.
LifeVantage Corp. employs 209 people — $874K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own LifeVantage Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research reported that LifeVantage Corp. (LFVN), along with CWH and CGAU, was added to the Zacks Rank #5 (Strong Sell) List on October 19, 2026.
Why it matters — LFVN watchers may note the stock’s addition to Zacks’ Strong Sell list.
LifeVantage announced that its board granted inducement awards to President and CEO Terrence Moorehead under its 2026 New Employee Long-Term Incentive Plan. The awards were granted under his key executive benefits agreement as an inducement to his employment, pursuant to Nasdaq Listing Rule 5635(c)(4).
Why it matters — LFVN watchers may note the executive compensation awards and the agreement supporting them.
LifeVantage executives outlined a turnaround plan during a Water Tower Research conference discussion, centered on strengthening the company's brand, improving consumer relevance, and increasing operating efficiency.
Why it matters — LFVN watchers would care because the company's leadership has publicly laid out a strategic direction focused on rebuilding the brand, improving margins, and restoring growth.
LifeVantage announced that CEO Terrence Moorehead and CFO Carl Aure will participate in the WTR Virtual Insights Conference on Wednesday, September 23, 2026. The announcement was made by the company on September 18, 2026.
Why it matters — Investors in LifeVantage may gain insight into the company's outlook when its top executives present at the virtual investor conference.
Seeking Alpha published a transcript of LifeVantage Corporation's Q4 2026 earnings call. The excerpt contains only the headline and source, with no details on the company's financial results or commentary.
Why it matters — A LifeVantage watcher would care because the earnings call transcript provides direct insight into the company's quarterly performance and management's outlook.
The 2 Wall Street analysts covering LifeVantage Corp. have a median 12-month price target of $7.5, with estimates ranging from $6 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering LifeVantage Corp., 1 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LifeVantage Corp. 80 out of 100 across roughly 4,600 US stocks as at 23 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Oct 2026, LifeVantage Corp. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +27.8% from the last close, and Ticker Nerd's factor model ranks LifeVantage Corp. 80 out of 100 as at 23 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering LifeVantage Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LFVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $9 over the next 12 months.
LifeVantage Corp. returned -31.2% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
LifeVantage Corporation is a health and wellness company that develops and sells nutrigenomic activators, dietary supplements, nootropics, weight management products, and skin and hair care items. Its product portfolio includes Protandim, TrueScience, PhysIQ, Axio, and Petandim, which are marketed to support cellular health, personal care, energy, and wellness routines.
The most recent item we track (Zacks Investment Research, 19 Oct 2026): "New Strong Sell Stocks for October 19th". Zacks Investment Research reported that LifeVantage Corp. (LFVN), along with CWH and CGAU, was added to the Zacks Rank #5 (Strong Sell) List on October 19, 2026.
LifeVantage Corporation is a health and wellness company that develops and sells nutrigenomic activators, dietary supplements, nootropics, weight management products, and skin and hair care items. Its product portfolio includes Protandim, TrueScience, PhysIQ, Axio, and Petandim, which are marketed to support cellular health, personal care, energy, and wellness routines. The company serves customers through a direct-selling model and operates across international markets in the Americas, Asia-Pacific, and Europe. LifeVantage Corporation focuses on science-based consumer health products that combine nutrition, beauty, and wellness, giving it a distinct position in the global nutritional supplements and personal care market.
CEO Mr. Terrence O. Moorehead · 209 employees · United States · https://www.lifevantage.com
